Quantcast

Latest Opioid Stories

2014-09-30 08:32:31

KemPharm's Intellectual Property Estate Now Includes Composition of Matter Patents for Two Ligand Activated Technology (LAT) Opioid Prodrugs - KP511 and KP201 CORALVILLE, Iowa, Sept. 30, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity (NME) prodrugs, announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,816,083 to KemPharm...

2014-09-29 08:30:53

DARIEN, Conn., Sept. 29, 2014 /PRNewswire/ -- Cytogel Pharma announces the presentation at the 8th Annual Pain and Migraine Therapeutics Summit of a mechanism of action study conducted in the laboratory of Gavril Pasternak, MD, PhD at Memorial Sloan Kettering Cancer Center in New York City. Cyt-1010 is a chemically stabilized and peptidase resistant analog of endomorphin-1, is highly mu-selective, showing very poor affinity for delta and kappa opioid receptors. Despite its mu...

2014-09-26 08:25:31

SAN FRANCISCO, Sept. 26, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of MOVENTIG® (naloxegol) for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxatives. MOVENTIG is an investigational, peripherally-acting...

2014-09-25 12:29:14

CHICAGO, Sept. 25, 2014 /PRNewswire/ -- Prompted by a mother whose one-year-old son died tragically after a successful bone marrow transplant procedure, the Physician-Patient Alliance for Health & Safety today encouraged hospitals across the nation to join "Keep It On" -- a campaign aimed at protecting the lives and safety of children who are monitored with pediatric pulse oximetry following surgery. http://photos.prnewswire.com/prnvar/20131024/CG03341LOGO To help hospitals join the...

2014-09-24 08:29:17

National Fed Up! Coalition Holds Second Major Rally as Death Toll Climbs from Opioid Epidemic WASHINGTON, Sept. 24, 2014 /PRNewswire-USNewswire/ -- On Sunday, September 28, 2014, a coalition of consumer advocacy organizations, drug prevention groups, medical experts and addiction treatment providers will hold the second annual Fed Up! Rally to call for an immediate, coordinated and comprehensive federal response to the epidemic of opioid addiction and overdose deaths. The Rally will...

2014-09-23 08:31:17

Company Positioned to Advance Development of Novel Sodium Channel (NaV) Inhibitors Targeting Pain SAN FRANCISCO, Sept. 23, 2014 /PRNewswire/ -- SiteOne Therapeutics Inc. today announced the completion of its initial round of equity financing. Led by Sears Capital Management and Biobrit LLC, with additional investors Mission Bay Capital and Joe Zakrzewski, the $1.5 million financing positions SiteOne to advance its oral Na(V)1.7 inhibitor program for pain and to further develop its...

2014-09-23 08:31:03

KemPharm Joins CLADD in Support of Legislation from Health Canada to Encourage More Responsible Development and Administration of Prescription Opioids CORALVILLE, Iowa, Sept. 23, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity (NME) prodrugs, announced today that it received a No Objection Letter (NOL) from Health Canada to begin clinical trials in Canada for its lead...

2014-09-19 08:26:16

SAN FRANCISCO, Sept. 19, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced results from preclinical studies characterizing the analgesic profiles of a series of the company's internally-discovered oral, peripherally-acting kappa opioid receptor agonist molecules. The preclinical research candidates were created using Nektar's small molecule polymer medicinal chemistry platform. The analgesic properties of kappa receptor agonism are well described in the medical...

2014-09-16 12:31:25

SAN FRANCISCO, Sept. 16, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK((TM)) (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. Opioids play an important role in chronic pain relief...

2014-09-16 08:29:45

Results Validating the Multi-Modal Mechanism of Action Would Provide the Basis for Differentiating LevoCap ER from other Pain Therapies NEW YORK, Sept. 16, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc., (OTCBB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has entered into an agreement with Memorial Sloan Kettering Cancer Center (MSKCC) in a series of animal studies for levorphanol, the active ingredient of...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.